← Back to Search

Monoclonal Antibodies

Pegylated Interferon alpha 2b (peg-IFN-α2b) for HIV/AIDS (BEAT-2 Trial)

Phase 1
Waitlist Available
Led By Luis J Montaner, DVM, DPhil
Research Sponsored by Luis Montaner
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks after end of 30 week of immunotherapy (analytical treatment interruption)
Awards & highlights

BEAT-2 Trial Summary

This trial will study the safety and effectiveness of a combination of drugs to treat HIV.

Eligible Conditions
  • HIV/AIDS
  • HIV

BEAT-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks after end of 30 week of immunotherapy (analytical treatment interruption)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks after end of 30 week of immunotherapy (analytical treatment interruption) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Association between antibody-mediated cell cytotoxicity (ADCC) and NK cell activation as measured by flowcytometry at start of step 4 therapy interruption and level of HIV plasma viral load 8 week later [Innate Activation outcome]
Frequency of subjects with plasma viral load <50 copies/ml after end of step 4 after ART therapy interruption [Virological outcome]
Treatment-related adverse events during 30 week period of immunotherapy [Safety outcome]

BEAT-2 Trial Design

2Treatment groups
Experimental Treatment
Group I: bNAb onlyExperimental Treatment1 Intervention
bNAb (3BNC117 + 10-10-74) only
Group II: Pegylated Interferon alpha 2b + bNAbsExperimental Treatment2 Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,884 Previous Clinical Trials
5,054,371 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,268 Previous Clinical Trials
5,480,685 Total Patients Enrolled
Luis MontanerLead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Nature MedicineJournal
Antibody 10-1074 Suppresses Viremia in Hiv-1-infected Individuals
Caskey, Marina, Till Schoofs, Henning Gruell, Allison Settler, Theodora Karagounis, Edward F Kreider, Ben Murrell, et al.. 2017. “Antibody 10-1074 Suppresses Viremia in Hiv-1-infected Individuals”. Nature Medicine. Springer Science and Business Media LLC. doi:10.1038/nm.4268.
The Journal of Infectious DiseasesJournal
Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-associated HIV DNA Integration
Azzoni, Livio, Andrea S. Foulkes, Emmanouil Papasavvas, Angela M. Mexas, Kenneth M. Lynn, Karam Mounzer, Pablo Tebas, et al.. 2012. “Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-associated HIV DNA Integration”. The Journal of Infectious Diseases. Oxford University Press (OUP). doi:10.1093/infdis/jis663.
NatureJournal
HIV-1 Antibody 3BNC117 Suppresses Viral Rebound in Humans During Treatment Interruption
Scheid, Johannes F., Joshua A. Horwitz, Yotam Bar-On, Edward F. Kreider, Ching-Lan Lu, Julio C. C. Lorenzi, Anna Feldmann, et al.. 2016. “HIV-1 Antibody 3BNC117 Suppresses Viral Rebound in Humans During Treatment Interruption”. Nature. Springer Science and Business Media LLC. doi:10.1038/nature18929.
clinicaltrials.govStudy
Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)
Luis Montaner 2020. "Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03588715.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top